PHRM

PharmaTher (PHRM)

PharmaTher Holdings Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:CSE:PHRM

日付	受信時刻	ニュースソース	見出し	コード	企業名
2021/11/12	00 : 00	InvestorsHub NewsWire	PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch	CSE:PHRM	PharmaTher Holdings Ltd
2021/11/03	21 : 03	InvestorsHub NewsWire	PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch	CSE:PHRM	PharmaTher Holdings Ltd
2021/10/19	20 : 07	InvestorsHub NewsWire	PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products	CSE:PHRM	PharmaTher Holdings Ltd
2021/10/13	22 : 20	InvestorsHub NewsWire	PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome	CSE:PHRM	PharmaTher Holdings Ltd
2021/09/21	23 : 19	InvestorsHub NewsWire	PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund	CSE:PHRM	PharmaTher Holdings Ltd
2021/09/13	22 : 03	InvestorsHub NewsWire	PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022	CSE:PHRM	PharmaTher Holdings Ltd
2021/08/04	21 : 15	InvestorsHub NewsWire	PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis	CSE:PHRM	PharmaTher Holdings Ltd
2021/07/21	21 : 19	InvestorsHub NewsWire	PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation	CSE:PHRM	PharmaTher Holdings Ltd
2021/06/17	00 : 14	InvestorsHub NewsWire	PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression	CSE:PHRM	PharmaTher Holdings Ltd
2021/05/25	21 : 45	InvestorsHub NewsWire	PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease	CSE:PHRM	PharmaTher Holdings Ltd
2021/05/17	21 : 02	InvestorsHub NewsWire	PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease	CSE:PHRM	PharmaTher Holdings Ltd
2021/04/27	20 : 47	InvestorsHub NewsWire	PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..Cont	CSE:PHRM	PharmaTher Holdings Ltd
2021/04/20	21 : 00	InvestorsHub NewsWire	PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial	CSE:PHRM	PharmaTher Holdings Ltd
2021/04/16	00 : 32	InvestorsHub NewsWire	PharmaTher Provides Update on Psychedelic Product Programs	CSE:PHRM	PharmaTher Holdings Ltd
2021/03/02	21 : 34	InvestorsHub NewsWire	PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....Cont	CSE:PHRM	PharmaTher Holdings Ltd
2021/02/18	00 : 11	InvestorsHub NewsWire	PharmaTher Announces Sale of Psilocybin Program	CSE:PHRM	PharmaTher Holdings Ltd
2021/02/04	22 : 21	InvestorsHub NewsWire	PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA	CSE:PHRM	PharmaTher Holdings Ltd
2021/02/01	22 : 19	InvestorsHub NewsWire	PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine	CSE:PHRM	PharmaTher Holdings Ltd
2021/01/19	22 : 07	InvestorsHub NewsWire	PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation	CSE:PHRM	PharmaTher Holdings Ltd